Activity Overview
This educational activity is an archive of the live 19th Annual New York GU Cancers Congress® held March 13 to 14, 2026.
For more information about this educational activity, the faculty, and disclosures, please click here.
Target Audience
This educational activity is directed toward medical, surgical, and radiation oncologists involved in the treatment of patients with genitourinary (GU) malignancies. Urologists, fellows, nurse practitioners, nurses, physician assistants, pharmacists, researchers, nuclear medicine physicians, and other health care professionals interested in the treatment of GU malignancies may also participate.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Interpret advanced diagnostic and molecular testing strategies—including circulating tumor DNA and genomic profiling—for risk stratification and disease monitoring in GU malignancies
- Apply molecular and genomic test results to guide treatment selection and personalize care in patients with GU cancers
- Integrate emerging therapies with multidisciplinary strategies to optimize treatment sequencing and coordination across specialties
- Evaluate the toxicity profiles and management strategies for novel therapeutic agents used in GU malignancies, including targeted therapies, immunotherapies, and antibody-drug conjugates
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here